JP4965428B2 - セミカルバジド誘導体を含むフリーラジカル消去剤 - Google Patents
セミカルバジド誘導体を含むフリーラジカル消去剤 Download PDFInfo
- Publication number
- JP4965428B2 JP4965428B2 JP2007505943A JP2007505943A JP4965428B2 JP 4965428 B2 JP4965428 B2 JP 4965428B2 JP 2007505943 A JP2007505943 A JP 2007505943A JP 2007505943 A JP2007505943 A JP 2007505943A JP 4965428 B2 JP4965428 B2 JP 4965428B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- nmr
- dmso
- methanol
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1ccc(C=O)cc1 Chemical compound *c1ccc(C=O)cc1 0.000 description 1
- GNWLDEDHYUOIDF-UHFFFAOYSA-N CNNC(NN)=O Chemical compound CNNC(NN)=O GNWLDEDHYUOIDF-UHFFFAOYSA-N 0.000 description 1
- XCBXPASVJXYAGQ-IZZDOVSWSA-N COc1ccc(/C=N/NC(NN)=O)cc1 Chemical compound COc1ccc(/C=N/NC(NN)=O)cc1 XCBXPASVJXYAGQ-IZZDOVSWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
- C07C281/08—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
- C07C281/14—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones the carbon atom being further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
- C07C337/08—Compounds containing any of the groups, e.g. thiosemicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. thiosemicarbazones
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/20—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen
- C09K15/22—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen containing an amide or imide moiety
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/26—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and sulfur
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/30—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing heterocyclic ring with at least one nitrogen atom as ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Birds (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Description
Rは、水素、あるいは非置換または1個以上の置換基で置換された、炭素原子数1〜4個のアルキル基、炭素原子数1〜4個のアルコキシ基、フェニル、ピリジル、フリルもしくはチエニル(前記置換基は、独立して、炭素原子数1〜4個のアルキル基、−OR2、−COOR2、−CN、−NO2もしくはハロゲン原子から選択され、R2は、水素もしくは炭素原子数1〜4個のアルキル基である)であり、
Xは、酸素原子または硫黄原子であり、
R1は、水素、−NH2または−N=CH−R’であり、そして
R’は、Rと同義であるが、Rと同一であってもまたは異なっていてもよい〕で示されるセミカルバジド誘導体またはその塩を含む、フリーラジカル消去剤に関する。
Rが、非置換または1〜3個の置換基で置換された、フェニル、ピリジルもしくはチエニル(前記置換基は、独立して、炭素原子数1〜4個のアルキル基、−OR2、−COOR2もしくはハロゲン原子から選択され、R2は、水素もしくは炭素原子数1〜4個のアルキル基である)であり、
Xが、酸素原子または硫黄原子であり、
R1が、水素、−NH2または−N=CH−R’であり、そして
R’が、Rと同一である、前記一般式(1)で示されるセミカルバジド誘導体またはその塩を含む、フリーラジカル消去剤に関する。
Arは、非置換または1〜3個の置換基で置換されたフェニル、ピリジルもしくはチエニル(前記置換基は、独立して、炭素原子数1〜4個のアルキル基、−OR2’、−COOR2’もしくはハロゲン原子から選択され、R2’は、水素もしくは炭素原子数1〜4個のアルキル基である)であり、
Xは、酸素原子または硫黄原子であり、そして
R1’は、−NH2または−N=CH−Arである〕で示されるセミカルバジド誘導体またはその塩に関する。
(1)N−(2−チエニルメチレン)チオカルボノヒドラジド、
(2)N−(2−チエニルメチレン)カルボノヒドラジド、
(3)1,5−ビス(2−チエニルメチレン)チオカルボノヒドラジド、
(4)N−(4−ピリジルメチレン)チオカルボノヒドラジド、
(5)N−(4−ピリジルメチレン)カルボノヒドラジド、
(6)1,5−ビス(4−ピリジルメチレン)チオカルボノヒドラジド、
(7)1,5−ビス(4−ピリジルメチレン)カルボノヒドラジド、
(8)N−(4−メトキシベンジリデン)チオカルボノヒドラジド、
(9)N−(4−メトキシベンジリデン)カルボノヒドラジド、
(10)1,5−ビス(4−メトキシベンジリデン)チオカルボノヒドラジド、
(11)1,5−ビス(4−フルオロベンジリデン)チオカルボノヒドラジド、
(12)N−(4−カルボキシベンジリデン)チオカルボノヒドラジド、
(13)N−(4−カルボキシベンジリデン)カルボノヒドラジド、
(14)1,5−ビス(4−カルボキシベンジリデン)チオカルボノヒドラジド、
(15)1,5−ビス(4−カルボキシベンジリデン)カルボノヒドラジド、
(16)N−(4−ヒドロキシベンジリデン)チオカルボノヒドラジド、
(17)N−(4−ヒドロキシベンジリデン)カルボノヒドラジド、
(18)1,5−ビス(4−カルボキシベンジリデン)チオカルボノヒドラジド、
(19)1,5−ビス(4−カルボキシベンジリデン)カルボノヒドラジド、
(20)1−(2,4−ジヒドロキシベンジリデン)チオセミカルバジド、
(21)N−(2,4−ジヒドロキシベンジリデン)チオカルボノヒドラジド、
(22)1,5−ビス(2,4−ジヒドロキシベンジリデン)チオカルボノヒドラジド、
(23)1,5−ビス(2,4−ジヒドロキシベンジリデン)カルボノヒドラジド、
(24)N−(2,4,6−トリヒドロキシベンジリデン)チオカルボノヒドラジド、
(25)N−(2,4,6−トリヒドロキシベンジリデン)カルボノヒドラジド、
(26)N−(3,4,5−トリヒドロキシベンジリデン)チオカルボノヒドラジド、
(27)N−(3,4,5−トリヒドロキシベンジリデン)カルボノヒドラジド
(28)1,5−ビス(3,4,5−トリヒドロキシベンジリデン)チオカルボノヒドラジド。
反応は、セミカルバジドまたはチオセミカルバジドに対し、アルデヒドを0.9〜1.5当量、好ましくは1〜1.2当量、最も好ましくは1.0当量用いて実施される。
一般式(1b)の化合物を主生成物として得るためには、反応は、カルボヒドラジドまたはチオカルボヒドラジドに対し、アルデヒドを0.9〜1.5当量、好ましくは1〜1.2当量、最も好ましくは1.0当量用いて実施される。一方、一般式(1c)の化合物を主生成物として得るためには、反応は、カルボヒドラジドまたはチオカルボヒドラジドに対し、アルデヒドを1.5〜2.5当量、好ましくは2〜2.2当量、最も好ましくは2.0当量用いて実施される。なお一般式(1)で示されるセミカルバジド誘導体において、R1が、−N=CH−R’であり、RとR’とが異なるセミカルバジド誘導体は、得られた一般式(1b)の化合物を、さらに異なるアルデヒドと反応させることにより得ることができる。
収量:0.02g(40%)
m.p.192℃
1H−NMR(DMSO)δ 4.83(s,NH2,1H),7.18(t,C−H,J=3.67Hz,1H),7.42(d,C−H,J=3.30Hz,1H),7.62(d,C−H,J=5.138Hz,1H),8.18(s,C−H,1H),9.38(s,N−H,1H),11.40(s,N−H,1H)
13C−NMR(DMSO)δ 127.82,128.73,130.24,137.34(C−H),138.68,175.49(C)
Anal.Calcd for C6H8N4S2:C,35.98;H,4.03;N,27.97.Found:C,36.11;H,3.84;N,28.25.
EI−MS m/z 200(M+)
収量:0.08g(45%)
m.p.162℃
1H−NMR(DMSO)δ 4.19(s,NH2,2H),7.15(t,C−H,J=3.85Hz,1H),7.42(d,C−H,J=3.48Hz,1H),7.65(d,C−H,J=4.40Hz,1H),8.14(s,C−H,1H),8.41(s,N−H,1H),10.58(s,N−H,1H)
13C−NMR(DMSO)δ 127.25,128.70,129.41,135.82(C−H),139.40,156.71(C)
EI−MS m/z 184(M+)
収量:0.13g(42%)
m.p.180〜184℃
1H−NMR(DMSO)δ 7.12(d,C−H,J=4.955Hz,2H),7.13(t,C−H,J=4.405Hz,2H),7.67(d,C−H,J=4.955Hz,2H),7.46(s,C−H,2H),11.56(s,N−H,2H)
13C−NMR(DMSO)δ 127.86,129.09,130.84(C−H),138.49,173.99(C)
FAB−MS m/z 295(M+1)
収量:0.54g(27%)
m.p.211〜215℃
1H−NMR(DMSO)δ 4.92(s,NH2,2H),7.80(d,C−H,J=1.27Hz,2H),8.57(d,C−H,J=1.45Hz,2H),10.05(s,N−H,1H),11.66(s,N−H,1H)
13C−NMR(DMSO)δ 121.14,139.15,149.92(C−H),141.53,175.75(C)
EI−MS m/z 195(M+)
収量:0.15g(30%)
m.p.207〜209℃
1H−NMR(DMSO)δ 4.17(s,NH2,2H),7.79(d,C−H,J=5.689Hz,2H),7.86(s,C−H,1H),8.60(d,C−H,J=5.872Hz,2H),8.31(s,N−H,1H),10.76(s,N−H,1H)
13C−NMR(DMSO)δ 120.68,137.31,149.87(C−H),141.94,156.67(C)
EI−MS m/z 179(M+)
収量:0.50g(17%)
m.p.218℃
1H−NMR(DMSO)δ 7.76(s,C−H,4H),7.82(s,C−H,2H),8.67(d,C−H,J=6.1Hz,4H),11.68(s,N−H,2H)
13C−NMR(DMSO)δ 121.19,141.18,150.18(C−H),141.00,175.61(C)
EI−MS m/z 284(M+)
収量:0.10g(34%)
m.p.218℃
1H−NMR(DMSO)δ 7.76(s,C−H,4H),7.82(s,C−H,2H),8.67(d,C−H,J=6.056Hz,4H),11.68(s,N−H,2H)
13C−NMR(DMSO)δ 121.19,141.18,150.18(C−H),141.00,175.61(C)
EI−MS m/z:268(M+)
収率:0.12g(52%)
m.p.182℃
1H−NMR(DMSO)δ 3.34(s,CH3,3H),4.81(s,NH2,2H),6.93(d,C−H,J=8.625Hz,2H),7.75(d,C−H,J=8.625Hz,2H),7.93(s,C−H,1H),9.70(s,N−H,1H),11.28(s,N−H,1H)
13C−NMR(DMSO)δ 55.26(CH3),126.86,114.08,128.94,142.04(C−H),126.86,160.56,175.77(C)
Anal.Calcd for C9H10N4OS:C,48.20;H,5.39;N,24.98.Found:C,48.36;H,5.31;N,25.28.
EI−MS m/z:224(M+)
収量:0.12g(58%)
m.p.181℃
1H−NMR(DMSO)δ 3.76(s,CH3,3H),4.03(s,NH2,2H),6.91(d,C−H,J=8.809Hz,2H),7.66(d,C−H,J=8.809Hz,2H),7.77(s,C−H,1H),7.91(s,N−H,1H),10.21(s,N−H,1H)
13C−NMR(DMSO)δ 55.20(CH3),114.02,128.17,140.01(C−H),127.39,157.22,160.05(C)
Anal.Calcd for C9H12N4O2:C,51.92;H,5.81;N,26.91.Found:C,52.12;H,5.76;N,27.42.
EI−MS m/z 209(M+1)
収量:0.28g(82%)
m.p.135〜136℃
1H−NMR(DMSO)δ 3.79(s,CH3,6H),7.00(d,C−H,J=8.61Hz,4H),7.71(s,C−H,4H),8.08(s,C−H,2H),11.07(s,N−H,2H)
13C−NMR(DMSO)δ 55.27(CH3),114.23,129.30,129.98(C−H),128.85,160.81,174.21(C)
FAB−MS m/z 343(M+1)
収量:0.20g(63%)
m.p.228℃
1H−NMR(DMSO)δ 7.28(t,C−H,J=8.8Hz,4H),7.87(s,C−H,4H),8.13(s,C−H,2H),11.58(s,N−H,2H)
13C−NMR(DMSO)δ 115.72,129.44,129.58(C−H),130.80,164.80,174.88(C)
FAB−MS m/z 318(M+)
収率:0.22g(90%)
m.p.>300℃
1H−NMR(DMSO)δ 7.91(d,C−H,J=8.625Hz,2H),7.94(d,C−H,J=8.625Hz,2H),8.03(s,C−H,1H),11.54(s,N−H,1H)
13C−NMR(DMSO)δ 127.27,129.49,140.73(C−H),131.18,138.48,166.98,175.75(C)
EI−MS m/z 238(M+)
収量:0.15g(66%)
m.p.>300℃
1H−NMR(DMSO)δ 7.84(d,C−H,J=8.442Hz,2H),7.89(s,C−H,1H),7.91(d,C−H,J=8.442Hz,2H),8.14(s,N−H,1H),10.54(s,N−H,1H)
13C−NMR(DMSO)δ 126.61,129.47,138.87(C−H),130.75,156.85,167.03(C)
EI−MS m/z 222(M+)
収量:0.314g(88%)
m.p.284〜287℃
1H−NMR(DMSO)δ 7.89−7.98(m,C−H,8H),8.66(s,C−H,2H),11.55(s,N−H,2H),12.10(s,COOH,2H)
13C−NMR(DMSO)δ 127.32,129.74,140.71(C−H),131.70,142.48,166.96,175.22(C)
EI−MS m/z 370(M+)
収量:0.29g(82%)
m.p.>300℃
1H−NMR(DMSO)δ 7.85(d,C−H,J=8.258Hz,4H),7.97(d,C−H,J=8.071Hz,4H),8.24(s,C−H,2H),10.92(s,N−H,2H)
13C−NMR(DMSO)δ 126.79,129.63,141.25(C−H),130.67,131.13,150.84,166.96(C)
FAB−MS m/z 355(M+1)
収率:0.18g(87%)
m.p.226℃
1H−NMR(DMSO)δ 4.80(s,NH2,2H),6.75(d,C−H,J=8.609Hz,2H),7.62(d,C−H,J=8.472Hz,2H),7.89(s,C−H,1H),9.59(s,N−H,1H),11.22(s,N−H,1H)
13C−NMR(DMSO)δ 115.48,129.09,1142.55(C−H),125.27,159.13,175.76(C)
EI−MS m/z 210(M+)
収量:0.11g(51%)
m.p.232℃
1H−NMR(DMSO)δ 4.04(s,NH2,2H),6.74(d,Ph−H,J=8.25,2H),7.53(d,Ph−H,J=8.44,2H),7.73(s,C−H,1H)
13C−NMR(DMSO)δ 115(CH),125(C),128(CH),140(CH),157(C=O),158(C−OH)
FT−IR(KBr)ν 3429(−NH2),3318(−NH),1697(C=O)
Anal.Calcd for C8H10N4O2:C,49.48;H,5.19;N,28.85.Found:C,50.22;H,5.12;N,27.35.
EI−MS m/z 194(M+)
収量:0.24g(76%)
m.p.222〜225℃
1H−NMR(DMSO)δ 6.82(d,C−H,J=8.624Hz,4H),7.61(d,C−H,J=16.69Hz,4H),8.03(s,C−H,2H),9.89(s,N−H,2H)
13C−NMR(DMSO)δ 115.61,128.85,129.10(C−H),125.11,159.38,173.95(C)
FAB−MS m/z 315(M+1)
収量:0.12g(42%)
m.p.261〜262℃
1H−NMR(DMSO)δ 6.81(d,C−H,J=8.625Hz,4H),7.56(d,C−H,J=8.441Hz,4H),8.05(s,C−H,2H),9.76(s,O−H,2H),10.36(s,N−H,2H)
13C−NMR(DMSO)δ 115.50,128.31,143.09(C−H),125.70,152.14,158(C)
FAB−MS m/z 299(M+1)
収量:0.16g(77%)
m.p.209−210℃
1H−NMR(DMSO)δ 6.27(s,OH,1H),6.28(s,OH,1H),7.65(d,CH,J=8.4Hz,1H),7.73(d,CH,J=8.4Hz,1H),7.92(s,CH,1H),9.79(s,NH2,2H),11.16(s,NH,1H)
EI−MS m/z 211(M+)
収量:0.17g(74%)
m.p.216〜219℃
1H−NMR(DMSO)δ 4.80(s,NH2,2H),6.27(d,C−H,J=6.24Hz,1H),6.28(s,C−H,1H),6.34(d,C−H,J=10.11Hz,1H),8.21(s,N−H,1H),9.53(s,N−H,1H)
13C−NMR(DMSO)δ 102.31,107.60,128.80,140.92(C−H),129.45,156.21,160.25,175.73(C)
EI−MS m/z 226(M+)
収量:0.24g(68%)
m.p.256〜260℃
1H−NMR(DMSO)δ 6.32(s,CH,2H),6.38(d,C−H,J=8.442Hz,2H),7.40(d,C−H,J=8.442Hz,2H),9.86(s,NH,2H)
13C−NMR(DMSO)δ 102.44,107.60,108.18,132.92(C−H),110.20,160.65,162.03,173.41(C)
FAB−MS m/z 347(M+1)
収量:0.23g(70%)
m.p.237〜241℃
1H−NMR(DMSO)δ 6.29(s,C−H,2H),6.32(d,C−H,J=2.20Hz,2H),7.42(d,C−H,J=6.05Hz,2H),8.26(s,C−H,2H),10.50(s,N−H,2H)
13C−NMR(DMSO)δ 102.49,107.44,129.95(C−H),111.44,152.01,158.31,159.95(C)
FAB−MS m/z 331(M+1)
収量:0.05g(53%)
m.p.223〜225℃
1H−NMR(DMSO)δ 5.80(s,Ar,2H),8.61(s,CH=N,1H),9.69(br,NH,1H)
13C−NMR(DMSO)δ 94.34,144.22(CH),99.22,159.07,159.23,160.98(C)
EI−MS m/z 242(M+)
収量:0.06g(69%)
m.p.238−240℃
1H−NMR(DMSO)δ 5.78(s,Ar,2H),8.46(s,CH=N,1H),9.35(br,NH,1H),10.98(br,2H,NH2)
13C−NMR(DMSO)δ 94.34,144.11(CH),102.18,157.63,159.42,173.29(C)
FAB−MS m/z 227(M++1)
収量:0.04g(49%)
m.p.227〜229℃
1H−NMR(DMSO)δ 4.79(s,NH2,2H),6.69(s,C−H,2H),7.80(s,C−H,1H),8.66(s,N−H,1H),9.48(s,N−H,1H)
13C−NMR(DMSO)δ 106.66,143.47(C−H),124.48,135
EI−MS m/z 242(M+)
収量:0.06g(69%)
m.p.238〜240℃
1H−NMR(DMSO)δ 4.06(s,NH2,2H),6.60(s,C−H,2H),7.54(s,C−H,1H),7.60(s,N−H,1H),10.07(s,N−H,1H)
13C−NMR(DMSO)δ 105.86,141.39(C−H),125.09,134.85,146.04,157.15(C)
EI−MS m/z 226(M+)
収量:25mg(56%)
m.p.230〜232℃
1H−NMR(CD3OD)δ 6.81(s,CH=,2H),7.86(s,CH,2H),8.06(s,CH,2H)
13C−NMR(CD3OD)δ 102.40,124.35(C−H),147.12,154.13,161.32(C)
Anal.Calcd for C15H14N4O6S:C,47.62;H,3.73;N,14.81.Found:C,47.87;H,3.55;N,15.07.
EI−MS m/z 378(M+)
各合成例で得られた化合物を、エタノール(エタノールのみに溶解しないものに関しては10%DMF含有エタノール)に溶解し、DPPH(α,α−ジフェニル−β−ピクリルヒドラジル)反応液中に添加した。DPPH反応は内山らの方法(薬学雑誌88(6),678−683,1968)に準じて行った。すなわち、100μM DPPH、60%エタノール、40mM酢酸緩衝液(pH5.5)及び適当濃度の各検体溶液からなる5mlの反応液を30℃で30分間放置した後、517nmにおける吸光度を測定し、吸光度を50%減少させる検体の濃度をIC50として表した。結果を表1示す。なお、表中の化合物番号は、上記合成例の番号に対応する。対照として、エダラボン、アスコルビン酸(ビタミンC)およびα−トコフェロール(ビタミンE)を用いた。
0.5%カルボキシメチルセルロースナトリウム塩水溶液に溶解または懸濁した検体を1群10匹の雄性マウス(ddY系、体重18〜20g)に経口投与した。検体投与7日後の死亡匹数から50%致死量(LD50)をprobit法により算出した。結果を表2に示す。本発明の化合物は、1,000mg/kg投与しても死亡例がなかった。
ESR(電子スピン共鳴)を用い、ヒドロキシラジカル消去能の測定を行った。なお、スピントラップ剤としてDMPO(5,5−ジメチル−1−ピロリン−N−オキシド)を用い、以下:
(1)0.5mM FeSO4−DETAPAC※1 in 100mMリン酸緩衝液(pH7.4) 50μL
(※1:N,N−ビス−[2−ビス(カルボキシメチル)アミノエチル]グリシン)
(2)検体 100μL
(3)1/100(v/v)DMPO(または1/10(v/v)DMPO)/水 50μL
(4)0.1mM H2O2 in 100mMリン酸緩衝液(pH7.4) 50μL
を、(1)から順に添加混和した反応液を、ESR用扁平セルにとり、混和1分後にESR装置(TE300、日本電子製)を用いてMnを内部標準とし、次の条件でヒドロキシラジカルとDMPOとのアダクト(DMPO−OH)のESRスペクトルを測定した。なお、(2)の検体は、各合成例で得られた化合物を、炭酸ナトリウム水溶液で適当濃度に希釈することにより調製した。
ESR測定条件:
得られたESRスペクトルについて、既知濃度のTEMPOL(2,2,6,6−テトラメチル−4−ピペリジノール−1−オキシル)のスペクトルを標準として、スペクトルの面積からDMPO−OH量を算出した。検体を添加しない反応液をブランクとし、このDMPO−OH量を50%減少させる検体の濃度をIC50として表した。結果を表3に示す。
ESRを用い、スーパーオキシドラジカル消去能の測定を行った。なお、スピントラップ剤としてDMPOを用い、以下:
(1)2mMヒポキサンチンin 100mMリン酸緩衝液(pH7.4) 50μL
(2)5.5mM DETAPAC in 100mM Na/Naリン酸緩衝液(pH7.4) 35μL
(3)検体 25μL
(4)8.0M DMSO 25μL
(5)DMPO原液 15μL
(6)0.2unit/mL XOD※2 in 100mM Na/Naリン酸緩衝液(pH7.4) 50μL
(※2:キサンチンオキシダーゼ)
を、(1)から順に添加混和した反応液を、キャピラリにとって試料管にセットし、混和1分後にESR装置(TE300、日本電子製)を用いてMnを内部標準とし、次の条件でスーパーオキシドラジカルとDMPOとのアダクトのESRスペクトルを測定した。なお、(3)の検体は、試験例3と同様に調製した。
ESR測定条件:
得られたESRスペクトルについて、既知濃度のTEMPOLのスペクトルを標準として、スペクトルの面積からDMPO−OOH量を算出した。検体を添加しない反応液をブランクとし、このDMPO−OOH量を50%減少させる検体の濃度をIC50として表した。結果を表3に示す。
冷1.15%KClで灌流したラットの肝1gに150mM KCl−10mM Tris−HCl緩衝液(pH7.4)9mLを加え、10%(w/v)ホモジネートを調製した。
0.25mLの前記ホモジネート(肝組織として25mg)、90mM KCl、50mM Tris−HCl緩衝液(pH7.4)、2.5μM FeSO4、0.5mMアスコルビン酸から成る全量0.5mLの反応液に、検体0.05mL(試験例3と同様に調製したもの)を添加し、37℃で30分間インキュベートした後、冷13.3%トリクロロ酢酸(TCA)1.5mLを加えて反応を停止した。これに0.7%チオバルビツール酸2mLを加え、15分間沸騰させた後、5分間氷水中で冷却、60%TCA1mLを加え、H2Oで全量を5mLとして、水中に放置した。氷中冷却の25分後に遠心分離(3000rpm、10分間)し、上清の532nmにおける吸光度を紫外可視分光光度計(UV mini−1240、島津製)を用いて測定した。検体を添加しない反応液をブランクとし、吸光度を50%減少させる検体の濃度をIC50として表した。結果を表3に示す。
Claims (2)
- 一般式(1):
Rは、水素、あるいは非置換または1個以上の置換基で置換された、炭素原子数1〜4個のアルキル基、炭素原子数1〜4個のアルコキシ基、フェニル、ピリジル、フリルもしくはチエニル(前記置換基は、独立して、炭素原子数1〜4個のアルキル基、−OR2、−COOR2、−CN、−NO2もしくはハロゲン原子から選択され、R2は、水素もしくは炭素原子数1〜4個のアルキル基である)であり、
Xは、酸素原子または硫黄原子であり、
R1は、水素、−NH2または−N=CH−R’であり、そして
R’は、Rと同義であるが、Rと同一であってもまたは異なっていてもよい、
で示されるセミカルバジド誘導体またはその塩を含む、フリーラジカル消去剤。 - Rが、非置換または1〜3個の置換基で置換された、フェニル、ピリジルもしくはチエニル(前記置換基は、独立して、炭素原子数1〜4個のアルキル基、−OR2、−COOR2もしくはハロゲン原子から選択され、R2は、水素もしくは炭素原子数1〜4個のアルキル基である)であり、
Xが、酸素原子または硫黄原子であり、
R1が、水素、−NH2または−N=CH−R’であり、そして
R’が、Rと同一である、請求項1記載の一般式(1)で示されるセミカルバジド誘導体またはその塩を含む、フリーラジカル消去剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007505943A JP4965428B2 (ja) | 2005-02-28 | 2006-02-28 | セミカルバジド誘導体を含むフリーラジカル消去剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005053409 | 2005-02-28 | ||
JP2005053409 | 2005-02-28 | ||
JP2007505943A JP4965428B2 (ja) | 2005-02-28 | 2006-02-28 | セミカルバジド誘導体を含むフリーラジカル消去剤 |
PCT/JP2006/303703 WO2006093124A1 (ja) | 2005-02-28 | 2006-02-28 | セミカルバジド誘導体を含むフリーラジカル消去剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006093124A1 JPWO2006093124A1 (ja) | 2008-08-07 |
JP4965428B2 true JP4965428B2 (ja) | 2012-07-04 |
Family
ID=36941153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007505943A Expired - Fee Related JP4965428B2 (ja) | 2005-02-28 | 2006-02-28 | セミカルバジド誘導体を含むフリーラジカル消去剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4965428B2 (ja) |
WO (1) | WO2006093124A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5176401B2 (ja) * | 2007-06-18 | 2013-04-03 | 東亞合成株式会社 | (メタ)アクリル酸エステルの製造方法 |
CN102964283B (zh) * | 2012-11-13 | 2014-04-16 | 中山大学 | 4-氨基硫脲缩甲醛基苯甲(氨基酸)酰胺化合物及其应用 |
CN105802608B (zh) * | 2016-03-08 | 2018-10-23 | 温州医科大学 | 一种荧光探针的制备方法及其在铝离子检测中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3734757A (en) * | 1970-08-07 | 1973-05-22 | Canadian Patents Dev | Thiocarbohydrazone fungicides |
JPH1059956A (ja) * | 1996-08-22 | 1998-03-03 | Kikkoman Corp | 新規イソフラボン誘導体及びその製造法 |
WO2000038617A2 (en) * | 1998-12-24 | 2000-07-06 | Four Star Partners | Compositions and methods of using the same |
JP2003064359A (ja) * | 2001-08-24 | 2003-03-05 | Meiji Univ | 新規なピロロピロール化合物およびピロロピロール化合物を含む抗酸化剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE754164A (fr) * | 1969-08-15 | 1970-12-31 | Canadian Patents Dev | Fongicides et leur utilisation |
-
2006
- 2006-02-28 WO PCT/JP2006/303703 patent/WO2006093124A1/ja active Application Filing
- 2006-02-28 JP JP2007505943A patent/JP4965428B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3734757A (en) * | 1970-08-07 | 1973-05-22 | Canadian Patents Dev | Thiocarbohydrazone fungicides |
JPH1059956A (ja) * | 1996-08-22 | 1998-03-03 | Kikkoman Corp | 新規イソフラボン誘導体及びその製造法 |
WO2000038617A2 (en) * | 1998-12-24 | 2000-07-06 | Four Star Partners | Compositions and methods of using the same |
JP2003064359A (ja) * | 2001-08-24 | 2003-03-05 | Meiji Univ | 新規なピロロピロール化合物およびピロロピロール化合物を含む抗酸化剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006093124A1 (ja) | 2008-08-07 |
WO2006093124A1 (ja) | 2006-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2828777B2 (ja) | 置換チアゾリジンジオン誘導体 | |
AU2019319971A1 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer | |
FR2857966A1 (fr) | Produits aryl-heteroaromatiques, compositions les contenant et utilisation | |
Singhal et al. | Evaluation of reducing power assay of chalcone semicarbazones | |
JP2003300875A (ja) | インターロイキン12抑制剤 | |
JP4965428B2 (ja) | セミカルバジド誘導体を含むフリーラジカル消去剤 | |
EP2062885A1 (en) | Acid addition salts of imatinib and formulations comprising the same | |
Wang et al. | Based on 2-(difluoromethyl)-1-[4, 6-di (4-morpholinyl)-1, 3, 5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kα selective inhibitors | |
KR20140036312A (ko) | Parp 저해 활성을 갖는 신규 화합물 | |
RU2384579C2 (ru) | Орто-замещенное производное анилина и антиоксидантное лекарственное средство | |
AU2016304331B2 (en) | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. | |
WO2014064219A1 (fr) | Derives de 1 h-indole-3-carboxamide et leurs utilisation comme antagonistes du p2y12 | |
CH633541A5 (en) | Pharmacologically active substituted 1,2,4-triazines and medicaments containing these triazines | |
FR2855825A1 (fr) | Produits aryl-heteroaromatiques, compositions les contenant et utilisation | |
US9381260B2 (en) | Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents | |
KR20220070620A (ko) | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 | |
JPH10507446A (ja) | ビス−2−アミノピリジン類、その製造方法及び寄生虫感染を制御するためのその用途 | |
US20030176475A1 (en) | Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them | |
CN109824574B (zh) | 吲哚-3-甲酰胺类化合物及其应用 | |
WO2022244821A1 (ja) | 抗ウイルス活性等の生理活性を有する化合物 | |
Gosavi et al. | Design, Synthesis, Characterization and Biological Evaluation of Novel Thiazolidine-4-Ones | |
KR100307660B1 (ko) | 도파민재소비저해제 | |
Khodair et al. | Synthesis, theoretical investigation, ADMET studies, antimicrobial activity, and docking analysis of some novel imidazolidinone derivatives | |
KR20190043013A (ko) | 신규한 인다졸 유도체 및 이의 용도 | |
WO2001028991A1 (fr) | Derives thiooxamide de n-cycloalkyle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120327 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120329 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4965428 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150406 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |